HighTower Advisors
ENTA icon

HighTower Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

HighTower Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-14,703
Closed -$428K – 1843
2016
Q1 		$428K Buy
14,703
+260
+2% +$7.24K ﹤0.01% 1446
2015
Q4 		$478K Buy
+14,443
New +$471K 0.01% 1339

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

HighTower Advisors's ENTA Position: Q2 2016 in Review

HighTower Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2016, closing a stake of 14,703 shares — an estimated $428K sold.

HighTower Advisors first reported a position in ENTA in Q4 2015 and held it in 2 quarters. The position peaked at $478K in Q4 2015. 129 funds tracked by Wall St. Rank hold ENTA as of Q2 2016.

  • HighTower Advisors reported no remaining Enanta Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • HighTower Advisors sold 14,703 Enanta Pharmaceuticals shares in Q2 2016, an estimated $428K.
  • HighTower Advisors first reported a position in Enanta Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • HighTower Advisors's Enanta Pharmaceuticals position peaked at $478K in Q4 2015.
  • 129 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2016.

Based on HighTower Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.